Amended Statement of Beneficial Ownership (3/a)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Aubrey de Lavenu Harold Andre

2. Date of Event Requiring Statement (MM/DD/YYYY) 7/12/2017

3. Issuer Name and Ticker or Trading Symbol

CEN BIOTECH INC [CENBF]

(Last) (First) (Middle)

300-3295 QUALITY WAY

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

WINDSOR, ONTARIO, CANADA, A6 N8T 3R9

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)
4/22/2021

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13321 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Convertible Note	5/24/2016	⁽³⁾	Common Stock	62500 ⁽²⁾	$1.6000	D
Convertible Note	11/25/2016	⁽³⁾	Common Stock	125000 ⁽²⁾	$1.6000	D
Convertible Note	12/14/2016	⁽³⁾	Common Stock	156250 ⁽²⁾	$1.6000	D
Convertible Note	2/9/2017	⁽³⁾	Common Stock	312500 ⁽²⁾	$1.6000	D

Explanation of Responses:
(1)	Harold Aubrey de Lavenu (the "Reporting Person") was appointed to his position with CEN Biotech, Inc. (the "Issuer") on July 12, 2017 and owned 13,321 shares of the Issuer's common stock on such date. On April 2, 2021, the Issuer appointed the Reporting Person to serve as a Vice President of the Issuer effective as of April 2, 2021
(2)	Additionally the Reporting Person owned convertible notes on July 12, 2017, which the Reporting Person purchased from the Issuer which were at such time and still are convertible into 656,250 shares of the Issuer's common stock.
(3)	The convertible notes included in this table matured on May 12, 2018, November 25, 2018, December 14, 2018, and February 19, 2019, respectively, (the "Maturity Dates"), however, the ability to convert the notes into shares did not expire on the Maturity Dates of the notes.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Aubrey de Lavenu Harold Andre 300-3295 QUALITY WAY WINDSOR, ONTARIO, CANADA, A6 N8T 3R9	X

Signatures
/s/ Harold Aubrey de Lavenu		5/28/2021
^**Signature of Reporting Person		Date

Grafico Azioni CEN Biotech (CE) (USOTC:CENBF)
Storico
Da Nov 2024 a Dic 2024

Grafico Azioni CEN Biotech (CE) (USOTC:CENBF)
Storico
Da Dic 2023 a Dic 2024

CENBF CEN Biotech Inc (CE)